Overview
NRF2 (Nuclear factor erythroid 2-related factor 2), encoded by the NFE2L2 gene, stands as the master regulator of cellular antioxidant response, controlling over 500 target genes involved in oxidative stress defense, detoxification, mitochondrial function, and inflammation1Alantolactone suppresses inflammation, apoptosis and oxidative stress in cigarette smoke-induced human bronchial epithelial cells through activation of Nrf2/HO-1 and inhibition of the NF-κB pathways.Open reference 1Alantolactone suppresses inflammation, apoptosis and oxidative stress in cigarette smoke-induced human bronchial epithelial cells through activation of Nrf2/HO-1 and inhibition of the NF-κB pathways.Open reference. First characterized in 1995 as a transcriptional activator of the β-globin gene, NRF2 has emerged as a critical protector against oxidative damage in virtually every tissue, including the brain4Fucoidan ameliorates lipid accumulation, oxidative stress, and NF-κB-mediated inflammation by regulating the PI3K/AKT/Nrf2 signaling pathway in a free fatty acid-induced NAFLD spheroid model.Open reference 2Fucoidan ameliorates lipid accumulation, oxidative stress, and NF-κB-mediated inflammation by regulating the PI3K/AKT/Nrf2 signaling pathway in a free fatty acid-induced NAFLD spheroid model.Open reference. Dysregulated NRF2 signaling contributes to pathogenesis in **Alzheimer’s disease (AD)**5Phloretin as a Multitarget Neuroprotective Agent: Mechanistic Insights into the Modulation of Oxidative Stress, Inflammation, and Apoptosis.Open reference, **Parkinson’s disease (PD)**6Phloretin as a Multitarget Neuroprotective Agent: Mechanistic Insights into the Modulation of Oxidative Stress, Inflammation, and Apoptosis.Open reference, **amyotrophic lateral sclerosis (ALS)**7The immunological challenges of cell transplantation for the treatment of Parkinson's disease.Open reference, **Huntington’s disease (HD)**8Phloretin as a Multitarget Neuroprotective Agent: Mechanistic Insights into the Modulation of Oxidative Stress, Inflammation, and Apoptosis.Open reference, **multiple sclerosis (MS)**9Phloretin as a Multitarget Neuroprotective Agent: Mechanistic Insights into the Modulation of Oxidative Stress, Inflammation, and Apoptosis.Open reference, and increasingly recognized in frontotemporal dementia and prion diseases 3Nrf2 signaling pathway: focus on oxidative stress in osteoporosis.Open reference.
The NRF2 pathway represents one of the most important cellular defense mechanisms against environmental and endogenous stressors. Under basal conditions, NRF2 is continuously synthesized and degraded, maintaining a low protein level. Upon exposure to oxidative stress or electrophilic compounds, NRF2 escapes degradation, translocates to the nucleus, and activates a battery of protective genes2Fucoidan ameliorates lipid accumulation, oxidative stress, and NF-κB-mediated inflammation by regulating the PI3K/AKT/Nrf2 signaling pathway in a free fatty acid-induced NAFLD spheroid model.Open reference0. This rapid response system is essential for cellular survival in the face of constant oxidative challenges from metabolism, mitochondria, and environmental toxins. The biological significance of NRF2 is underscored by the lethal phenotype of Nfe2l2 knockout mice, which die perinatally due to severe oxidative stress2Fucoidan ameliorates lipid accumulation, oxidative stress, and NF-κB-mediated inflammation by regulating the PI3K/AKT/Nrf2 signaling pathway in a free fatty acid-induced NAFLD spheroid model.Open reference1.
Oxidative stress plays a central role in neurodegenerative processes, with evidence of elevated reactive oxygen species (ROS), lipid peroxidation, protein oxidation, and DNA damage in post-mortem brain tissue from patients with various neurodegenerative disorders2Fucoidan ameliorates lipid accumulation, oxidative stress, and NF-κB-mediated inflammation by regulating the PI3K/AKT/Nrf2 signaling pathway in a free fatty acid-induced NAFLD spheroid model.Open reference2. The brain’s high metabolic rate, elevated lipid content, and relatively limited antioxidant capacity make it particularly vulnerable to oxidative insults. NRF2 activation provides a critical defensive response that can counteract these pathological processes, making it an attractive therapeutic target.
NRF2 Structure and Function
Protein Architecture and Evolution
The NRF2 protein contains six highly conserved domains (Neh1-6) that mediate its transcriptional activity, protein interactions, and regulatory mechanisms2Fucoidan ameliorates lipid accumulation, oxidative stress, and NF-κB-mediated inflammation by regulating the PI3K/AKT/Nrf2 signaling pathway in a free fatty acid-induced NAFLD spheroid model.Open reference3. This modular architecture allows NRF2 to integrate multiple upstream signals and execute precise transcriptional programs.
Neh1 Domain: Located at the N-terminus, this basic leucine zipper (bZIP) motif is essential for heterodimerization with small Maf (sMaf) proteins, including MAFF, MAFG, and MAFK, and direct DNA binding to Antioxidant Response Elements (ARE)2Fucoidan ameliorates lipid accumulation, oxidative stress, and NF-κB-mediated inflammation by regulating the PI3K/AKT/Nrf2 signaling pathway in a free fatty acid-induced NAFLD spheroid model.Open reference4. The bZIP structure forms a classical helix-loop-helix configuration that recognizes specific DNA sequences. Crystal structures reveal that the Neh1 domain forms a stable heterodimer with Maf proteins, creating a functional DNA-binding complex2Fucoidan ameliorates lipid accumulation, oxidative stress, and NF-κB-mediated inflammation by regulating the PI3K/AKT/Nrf2 signaling pathway in a free fatty acid-induced NAFLD spheroid model.Open reference5.
Neh2 Domain: This N-terminal regulatory domain contains two degron motifs—ETGE and DLG—that are essential for binding to KEAP1 (Kelch-like ECH-associated protein 1)2Fucoidan ameliorates lipid accumulation, oxidative stress, and NF-κB-mediated inflammation by regulating the PI3K/AKT/Nrf2 signaling pathway in a free fatty acid-induced NAFLD spheroid model.Open reference6. The high-affinity ETGE motif and lower-affinity DLG motif work cooperatively to orchestrate NRF2 ubiquitination. The Neh2 domain also contains seven serine residues (Ser-40 being the most critical) whose phosphorylation dramatically affects NRF2 stability and nuclear translocation2Fucoidan ameliorates lipid accumulation, oxidative stress, and NF-κB-mediated inflammation by regulating the PI3K/AKT/Nrf2 signaling pathway in a free fatty acid-induced NAFLD spheroid model.Open reference7. Mutations in these degron motifs lead to constitutive NRF2 activation and resistance to oxidative stress-induced degradation.
Neh3, Neh4, and Neh5: These transactivation domains recruit transcriptional coactivators including CBP/p300, BRG1 (brahma-related gene 1), and other chromatin remodeling proteins2Fucoidan ameliorates lipid accumulation, oxidative stress, and NF-κB-mediated inflammation by regulating the PI3K/AKT/Nrf2 signaling pathway in a free fatty acid-induced NAFLD spheroid model.Open reference8. Neh3, located at the C-terminus, is essential for full transcriptional activation and interacts with the chromodomain helicase DNA-binding protein 7 (CHD7)2Fucoidan ameliorates lipid accumulation, oxidative stress, and NF-κB-mediated inflammation by regulating the PI3K/AKT/Nrf2 signaling pathway in a free fatty acid-induced NAFLD spheroid model.Open reference9. Neh4 and Neh5 function synergistically, with Neh5 containing multiple acidic amino acid clusters that facilitate binding to coactivators3Nrf2 signaling pathway: focus on oxidative stress in osteoporosis.Open reference0.
Neh6 Domain: This serine-rich domain (containing 12 serine and 4 threonine residues) contributes to NRF2 regulation through β-TrCP (beta-transducin repeat-containing protein)-dependent degradation3Nrf2 signaling pathway: focus on oxidative stress in osteoporosis.Open reference1. The Neh6 domain becomes particularly important under conditions of oxidative stress when KEAP1-mediated degradation is inhibited, providing an alternative degradation pathway that maintains some control over NRF2 levels.
flowchart TD
A["NRF2 Protein"] --> B["Neh1 Domain<br/>bZIP - DNA Binding"]
A --> C["Neh2 Domain<br/>ETGE + DLG degrons<br/>Ser40 phosphorylation"]
A --> D["Neh3 Domain<br/>Transactivation"]
A --> E["Neh4 Domain<br/>Coactivator binding"]
A --> F["Neh5 Domain<br/>Transactivation"]
A --> G["Neh6 Domain<br/>beta-TrCP recognition"]
B --> H["Heterodimer with<br/>small Maf proteins"]
C --> I["KEAP1 binding"]
C --> J["Proteasomal degradation"]Canonical Activation: The KEAP1-NRF2 Pathway
The Kelch-like ECH-associated protein 1 (KEAP1)-NRF2 pathway represents the primary mechanism of NRF2 regulation and serves as a cellular sensor for oxidative and electrophilic stress3Nrf2 signaling pathway: focus on oxidative stress in osteoporosis.Open reference2.
KEAP1 Structure and Cysteine Sensing: KEAP1 is a cysteine-rich protein (containing 27 cysteine residues) that functions as an adaptor for the Cullin 3 (CUL3)-based E3 ubiquitin ligase complex3Nrf2 signaling pathway: focus on oxidative stress in osteoporosis.Open reference3. The KEAP1 protein comprises three major domains: the N-terminal Broad complex, Tramtrack and Bric-à-brac (BTB) domain, the intervening region (IVR), and six Kelch repeats at the C-terminus that form a six-bladed β-propeller structure3Nrf2 signaling pathway: focus on oxidative stress in osteoporosis.Open reference4. The BTB domain mediates KEAP1 homodimerization and interaction with CUL3, while the Kelch repeats provide the binding surface for the NRF2 degrons3Nrf2 signaling pathway: focus on oxidative stress in osteoporosis.Open reference5.
The cysteine residues of KEAP1 function as molecular sensors for oxidative stress. Among these, C151 in the BTB domain, C273 and C288 in the IVR, and C489 in the Kelch repeat domain are particularly critical for stress sensing3Nrf2 signaling pathway: focus on oxidative stress in osteoporosis.Open reference6. Modification of these cysteines by electrophilic compounds or oxidative stress disrupts the KEAP1-CUL3-RBX1 E3 ligase complex, preventing NRF2 ubiquitination. Structural studies have revealed that different cysteine modifications can lead to distinct conformational changes in KEAP1, potentially allowing for graded responses to varying levels of stress3Nrf2 signaling pathway: focus on oxidative stress in osteoporosis.Open reference7.
Mechanism of Degradation: Under basal conditions, NRF2 constantly binds to KEAP1 through its two degron motifs (ETGE and DLG)3Nrf2 signaling pathway: focus on oxidative stress in osteoporosis.Open reference8. The sequential binding model suggests that NRF2 initially binds KEAP1 through the high-affinity ETGE motif, followed by a conformational change that allows the DLG motif to engage, positioning NRF2 for ubiquitination3Nrf2 signaling pathway: focus on oxidative stress in osteoporosis.Open reference9. The CUL3-RBX1 complex then catalyzes the transfer of ubiquitin to NRF2, targeting it for proteasomal degradation1Alantolactone suppresses inflammation, apoptosis and oxidative stress in cigarette smoke-induced human bronchial epithelial cells through activation of Nrf2/HO-1 and inhibition of the NF-κB pathways.Open reference0. This turnover ensures that NRF2 levels remain low under non-stressed conditions while maintaining the capacity for rapid activation.
Stress-Induced Activation: Upon oxidative or electrophilic stress, modification of KEAP1 cysteines disrupts the KEAP1-CUL3-RBX1 E3 ligase complex, preventing NRF2 ubiquitination1Alantolactone suppresses inflammation, apoptosis and oxidative stress in cigarette smoke-induced human bronchial epithelial cells through activation of Nrf2/HO-1 and inhibition of the NF-κB pathways.Open reference1. Newly synthesized NRF2 accumulates and translocates to the nucleus through a process involving release from KEAP1 and recognition of nuclear localization signals1Alantolactone suppresses inflammation, apoptosis and oxidative stress in cigarette smoke-induced human bronchial epithelial cells through activation of Nrf2/HO-1 and inhibition of the NF-κB pathways.Open reference2. In the nucleus, NRF2 heterodimerizes with small Maf proteins and binds to Antioxidant Response Elements (ARE) in the promoters and enhancers of target genes1Alantolactone suppresses inflammation, apoptosis and oxidative stress in cigarette smoke-induced human bronchial epithelial cells through activation of Nrf2/HO-1 and inhibition of the NF-κB pathways.Open reference3. The consensus ARE sequence is 5’-TGACnnnGC-3’, which is found in the regulatory regions of many detoxifying and antioxidant genes1Alantolactone suppresses inflammation, apoptosis and oxidative stress in cigarette smoke-induced human bronchial epithelial cells through activation of Nrf2/HO-1 and inhibition of the NF-κB pathways.Open reference4.
flowchart LR
subgraph Basal
A["NRF2"] -->|"Binds"| B["KEAP1"]
B -->|"Recruits"| C["CUL3-RBX1<br/>E3 Ligase"]
C -->|"Ubiquitinates"| D["Proteasome"]
D -->|"Degrades"| A
end
subgraph Stressed
E["Oxidative Stress"] -->|"Modifies"| F["KEAP1 Cysteines"]
F -->|"Inhibits"| G["E3 Ligase Activity"]
G -->|"Prevents"| H["NRF2 Ubiquitination"]
H -->|"Accumulates"| I["NRF2"]
I -->|"Translocates"| J["Nucleus"]
J -->|"Binds ARE"| K["Target Gene<br/>Transcription"]
endNon-Canonical Activation Pathways
Alternative NRF2 activation mechanisms provide additional regulatory complexity and allow for tissue-specific or condition-specific responses1Alantolactone suppresses inflammation, apoptosis and oxidative stress in cigarette smoke-induced human bronchial epithelial cells through activation of Nrf2/HO-1 and inhibition of the NF-κB pathways.Open reference5.
p62-Dependent Activation: The autophagy adaptor protein p62 (SQSTM1) can sequester and inactivate KEAP1 through phosphorylation at Ser403, creating a positive feedback loop that amplifies NRF2 signaling1Alantolactone suppresses inflammation, apoptosis and oxidative stress in cigarette smoke-induced human bronchial epithelial cells through activation of Nrf2/HO-1 and inhibition of the NF-κB pathways.Open reference6. mTORC1 phosphorylation of p62 at Ser409 enhances this interaction, linking nutrient sensing and autophagy to antioxidant response1Alantolactone suppresses inflammation, apoptosis and oxidative stress in cigarette smoke-induced human bronchial epithelial cells through activation of Nrf2/HO-1 and inhibition of the NF-κB pathways.Open reference7. This pathway becomes particularly important under conditions of autophagy inhibition, where p62 accumulation leads to NRF2 activation as an compensatory response1Alantolactone suppresses inflammation, apoptosis and oxidative stress in cigarette smoke-induced human bronchial epithelial cells through activation of Nrf2/HO-1 and inhibition of the NF-κB pathways.Open reference8.
PKC-Dependent Activation: Protein kinase C (PKC) directly phosphorylates NRF2 at Ser40, promoting nuclear translocation independently of KEAP1 modification1Alantolactone suppresses inflammation, apoptosis and oxidative stress in cigarette smoke-induced human bronchial epithelial cells through activation of Nrf2/HO-1 and inhibition of the NF-κB pathways.Open reference9. This phosphorylation event reduces NRF2’s affinity for KEAP1 and facilitates its release into the cytoplasm. Multiple PKC isoforms, including PKCδ and PKCθ, have been implicated in this process4Fucoidan ameliorates lipid accumulation, oxidative stress, and NF-κB-mediated inflammation by regulating the PI3K/AKT/Nrf2 signaling pathway in a free fatty acid-induced NAFLD spheroid model.Open reference0.
PI3K/Akt Signaling: Phosphatidylinositol 3-kinase (PI3K) and its downstream effector Akt (protein kinase B) can activate NRF2 through phosphorylation at multiple sites4Fucoidan ameliorates lipid accumulation, oxidative stress, and NF-κB-mediated inflammation by regulating the PI3K/AKT/Nrf2 signaling pathway in a free fatty acid-induced NAFLD spheroid model.Open reference1. The PI3K/Akt pathway promotes NRF2 nuclear translocation and transcriptional activity, providing a link between growth factor signaling and antioxidant response.
MAPK Signaling: Various mitogen-activated protein kinases (MAPKs) can phosphorylate NRF2 at multiple serine and threonine residues, modulating its transcriptional activity in both positive and negative ways4Fucoidan ameliorates lipid accumulation, oxidative stress, and NF-κB-mediated inflammation by regulating the PI3K/AKT/Nrf2 signaling pathway in a free fatty acid-induced NAFLD spheroid model.Open reference2. ERK, JNK, and p38 MAPK have all been reported to phosphorylate NRF2, with the effects depending on the specific residues modified and the cellular context4Fucoidan ameliorates lipid accumulation, oxidative stress, and NF-κB-mediated inflammation by regulating the PI3K/AKT/Nrf2 signaling pathway in a free fatty acid-induced NAFLD spheroid model.Open reference3.
GSK-3β Inhibition: Glycogen synthase kinase-3 beta (GSK-3β) phosphorylates NRF2 at specific residues that promote its degradation through the β-TrCP-dependent pathway4Fucoidan ameliorates lipid accumulation, oxidative stress, and NF-κB-mediated inflammation by regulating the PI3K/AKT/Nrf2 signaling pathway in a free fatty acid-induced NAFLD spheroid model.Open reference4. Inhibition of GSK-3β by various signals, including PI3K/Akt and Wnt signaling, can therefore enhance NRF2 activity.
Target Gene Network
Antioxidant Response Elements
NRF2 controls a remarkably diverse set of genes involved in cellular protection, collectively termed the "NRF2 transcriptome"4Fucoidan ameliorates lipid accumulation, oxidative stress, and NF-κB-mediated inflammation by regulating the PI3K/AKT/Nrf2 signaling pathway in a free fatty acid-induced NAFLD spheroid model.Open reference5. The breadth of this response encompasses virtually every aspect of cellular defense and homeostasis.
Phase I Metabolism (Oxidation/Reduction):
-
Cytochrome P450 enzymes: CYP2A6, CYP2C9, CYP2E1, CYP3A4—metabolize xenobiotics and endogenous compounds4Fucoidan ameliorates lipid accumulation, oxidative stress, and NF-κB-mediated inflammation by regulating the PI3K/AKT/Nrf2 signaling pathway in a free fatty acid-induced NAFLD spheroid model.Open reference6
-
Aldehyde dehydrogenases: ALDH2, ALDH3A1—clear reactive aldehydes generated during lipid peroxidation4Fucoidan ameliorates lipid accumulation, oxidative stress, and NF-κB-mediated inflammation by regulating the PI3K/AKT/Nrf2 signaling pathway in a free fatty acid-induced NAFLD spheroid model.Open reference7
-
Alcohol dehydrogenases: ADH1, ADH6—participate in detoxificatio
Phase II Metabolism (Conjugation):
-
Glutathione S-transferases (GSTs): GSTA1, GSTM1, GSTP1, GSTZ1—conjugate toxins with glutathione4Fucoidan ameliorates lipid accumulation, oxidative stress, and NF-κB-mediated inflammation by regulating the PI3K/AKT/Nrf2 signaling pathway in a free fatty acid-induced NAFLD spheroid model.Open reference8
-
NAD(P)H:quinone oxidoreductase 1 (NQO1): Catalyzes quinone reduction, preventing redox cycling and oxidative stress4Fucoidan ameliorates lipid accumulation, oxidative stress, and NF-κB-mediated inflammation by regulating the PI3K/AKT/Nrf2 signaling pathway in a free fatty acid-induced NAFLD spheroid model.Open reference9
-
Uridine 5’-diphosphate (UDP)-glucuronosyltransferases (UGTs): Facilitate xenobiotic glucuronidation5Phloretin as a Multitarget Neuroprotective Agent: Mechanistic Insights into the Modulation of Oxidative Stress, Inflammation, and Apoptosis.Open reference0
Antioxidant Proteins:
-
Heme oxygenase-1 (HO-1/HMOX1): Degrades heme into biliverdin, iron, and carbon monoxide, providing potent anti-inflammatory and cytoprotective effects5Phloretin as a Multitarget Neuroprotective Agent: Mechanistic Insights into the Modulation of Oxidative Stress, Inflammation, and Apoptosis.Open reference1
-
Superoxide dismutase (SOD1, SOD2, SOD3): Convert superoxide anion to hydrogen peroxide5Phloretin as a Multitarget Neuroprotective Agent: Mechanistic Insights into the Modulation of Oxidative Stress, Inflammation, and Apoptosis.Open reference2
-
Glutathione peroxidases (GPx1, GPx2, GPx4): Reduce hydroperoxides, protecting against lipid peroxidation5Phloretin as a Multitarget Neuroprotective Agent: Mechanistic Insights into the Modulation of Oxidative Stress, Inflammation, and Apoptosis.Open reference3
-
Catalase (CAT): Decomposes hydrogen peroxide to water and oxygen5Phloretin as a Multitarget Neuroprotective Agent: Mechanistic Insights into the Modulation of Oxidative Stress, Inflammation, and Apoptosis.Open reference4
Proteostasis and Autophagy:
-
p62/SQSTM1: Autophagy adaptor that links ubiquitinated proteins to autophagosomes5Phloretin as a Multitarget Neuroprotective Agent: Mechanistic Insights into the Modulation of Oxidative Stress, Inflammation, and Apoptosis.Open reference5
-
Proteasome subunits (PSMA, PSMB): Enhance protein clearance and removal of damaged proteins5Phloretin as a Multitarget Neuroprotective Agent: Mechanistic Insights into the Modulation of Oxidative Stress, Inflammation, and Apoptosis.Open reference6
-
Sequestosome 1: Alternative name for p62, involved in aggrephagy
Mitochondrial Function:
-
TFAM: Mitochondrial transcription factor A, essential for mitochondrial DNA replication and transcription5Phloretin as a Multitarget Neuroprotective Agent: Mechanistic Insights into the Modulation of Oxidative Stress, Inflammation, and Apoptosis.Open reference7
-
PGC-1α (PPARGC1A): Master regulator of mitochondrial biogenesis and respiration5Phloretin as a Multitarget Neuroprotective Agent: Mechanistic Insights into the Modulation of Oxidative Stress, Inflammation, and Apoptosis.Open reference8
-
Mitochondrial uncoupling proteins (UCP2, UCP3): Modulate mitochondrial ROS production5Phloretin as a Multitarget Neuroprotective Agent: Mechanistic Insights into the Modulation of Oxidative Stress, Inflammation, and Apoptosis.Open reference9
Iron and Heme Metabolism:
-
Ferritin (FTH1, FTL): Iron storage proteins that sequester free iron and prevent Fenton chemistry6Phloretin as a Multitarget Neuroprotective Agent: Mechanistic Insights into the Modulation of Oxidative Stress, Inflammation, and Apoptosis.Open reference0
-
Transferrin (TF) and Transferrin Receptor (TFRC): Regulate iron uptake and distribution6Phloretin as a Multitarget Neuroprotective Agent: Mechanistic Insights into the Modulation of Oxidative Stress, Inflammation, and Apoptosis.Open reference1
NRF2 in Neurodegenerative Diseases
Alzheimer’s Disease
NRF2 activity is profoundly impaired in AD despite the presence of high oxidative stress, creating a pathogenic feed-forward cycle of oxidative damage and impaired defense6Phloretin as a Multitarget Neuroprotective Agent: Mechanistic Insights into the Modulation of Oxidative Stress, Inflammation, and Apoptosis.Open reference2.
Reduced Nuclear NRF2: Post-mortem studies consistently demonstrate decreased NRF2 nuclear localization in AD brains, particularly in the hippocampus and cortex—regions most affected by amyloid-β (Aβ) and tau pathology6Phloretin as a Multitarget Neuroprotective Agent: Mechanistic Insights into the Modulation of Oxidative Stress, Inflammation, and Apoptosis.Open reference3. This nuclear deficiency occurs despite elevated NRF2 cytoplasmic expression, suggesting impaired nuclear translocation rather than reduced protein synthesis6Phloretin as a Multitarget Neuroprotective Agent: Mechanistic Insights into the Modulation of Oxidative Stress, Inflammation, and Apoptosis.Open reference4. Immunohistochemical analysis reveals that NRF2 fails to activate in response to the intense oxidative stress present in AD brain tissue.
Mechanisms of NRF2 Dysfunction: Multiple mechanisms contribute to NRF2 impairment in AD6Phloretin as a Multitarget Neuroprotective Agent: Mechanistic Insights into the Modulation of Oxidative Stress, Inflammation, and Apoptosis.Open reference5:
-
Aβ oligomers directly interfere with NRF2 nuclear translocation
-
Hyperphosphorylated tau sequesters NRF2 in the cytoplasm
-
Chronic oxidative stress leads to KEAP1-independent NRF2 degradation
-
Age-related decline in NRF2 activation compounds disease-related dysfunction
Dysregulated Target Genes: NRF2 target genes show abnormal expression patterns that contribute to disease progression6Phloretin as a Multitarget Neuroprotective Agent: Mechanistic Insights into the Modulation of Oxidative Stress, Inflammation, and Apoptosis.Open reference6:
-
HO-1 is paradoxically elevated but with reduced enzymatic activity, suggesting compensatory upregulation that is functionally inadequate
-
NQO1 is reduced in early AD, compromising quinone detoxification
-
γ-Glutamylcysteine synthetase (GCLC, GCLM) is downregulated, contributing to glutathione depletion
-
Phase I and II detoxification enzymes are generally reduced
Therapeutic Potential: NRF2 activators show significant promise in AD models6Phloretin as a Multitarget Neuroprotective Agent: Mechanistic Insights into the Modulation of Oxidative Stress, Inflammation, and Apoptosis.Open reference7:
-
Sulforaphane reduces Aβ toxicity in cell models through NRF2-dependent mechanisms
-
Dimethyl fumarate improves cognition and reduces amyloid pathology in APP/PS1 mouse models
-
Bardoxolone methyl (CDDO-Me) activates NRF2 and shows beneficial effects in preliminary studies
-
NRF2 knockout mice demonstrate exacerbated amyloid pathology, confirming protective role6Phloretin as a Multitarget Neuroprotective Agent: Mechanistic Insights into the Modulation of Oxidative Stress, Inflammation, and Apoptosis.Open reference8
Parkinson’s Disease
NRF2 dysfunction is particularly prominent in PD, where dopaminergic neurons face unique oxidative challenges from dopamine metabolism, iron accumulation, and environmental toxins6Phloretin as a Multitarget Neuroprotective Agent: Mechanistic Insights into the Modulation of Oxidative Stress, Inflammation, and Apoptosis.Open reference9.
Dopamine Metabolism and Oxidative Stress: The metabolism of dopamine through monoamine oxidase (MAO) produces hydrogen peroxide, while autooxidation generates toxic dopamine quinones7The immunological challenges of cell transplantation for the treatment of Parkinson's disease.Open reference0. NRF2 activation provides critical protection against these reactive intermediates.
SNCA Impairment: α-Synuclein (SNCA) mutations and overexpression impair NRF2 activation through multiple mechanisms7The immunological challenges of cell transplantation for the treatment of Parkinson's disease.Open reference1:
-
Direct interference with KEAP1-NRF2 binding
-
Physical interaction with NRF2 that prevents nuclear translocation
-
Sequestration of NRF2 in cytoplasmic inclusions
-
Disruption of p62-mediated NRF2 activation
Environmental Toxins: PD-inducing environmental neurotoxins cause NRF2 dysregulation through distinct mechanisms7The immunological challenges of cell transplantation for the treatment of Parkinson's disease.Open reference2:
-
MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) causes transient NRF2 activation followed by pathway exhaustion
-
Rotenone inhibits complex I and induces sustained oxidative stress that overwhelms NRF2 defenses
-
6-Hydroxydopamine (6-OHDA) generates quinones that deplete cellular glutathione and impair NRF2 response
Genetic Associations: NRF2 promoter polymorphisms affect PD risk and progression7The immunological challenges of cell transplantation for the treatment of Parkinson's disease.Open reference3:
-
Promoter variants with reduced transcriptional activity are associated with increased PD risk
-
Polymorphisms correlate with earlier disease onset
-
Gene-environment interactions modify susceptibility
Therapeutic Approaches: NRF2 activation represents a priority for PD drug development7The immunological challenges of cell transplantation for the treatment of Parkinson's disease.Open reference4:
-
Sulforaphane protects dopaminergic neurons in MPTP and rotenone models
-
Dimethyl fumarate (Tecfidera) is in clinical trials for PD
-
Novel NRF2 activators including RSV (resveratrol) derivatives show promise
-
Gene therapy approaches to enhance NRF2 expression are under investigation
Amyotrophic Lateral Sclerosis
NRF2 dysfunction contributes to motor neuron vulnerability in ALS through multiple interconnected mechanisms7The immunological challenges of cell transplantation for the treatment of Parkinson's disease.Open reference5.
Reduced NRF2 Activity: ALS patient spinal cord demonstrates decreased NRF2 and target gene expression, particularly in motor neurons7The immunological challenges of cell transplantation for the treatment of Parkinson's disease.Open reference6. This impairment may predispose motor neurons to oxidative damage from multiple sources, including mitochondrial dysfunction, glutamate excitotoxicity, and neuroinflammation.
SOD1 Mutations: Mutant SOD1 proteins interfere with NRF2 signaling through several mechanisms7The immunological challenges of cell transplantation for the treatment of Parkinson's disease.Open reference7:
-
Direct interaction with NRF2 that prevents its transcriptional activity
-
Sequestration of KEAP1 that paradoxically leads to pathway dysregulation
-
Impaired nuclear translocation due to cytoplasmic aggregates
-
Disruption of p62-dependent autophagy
C9orf72 Repeat Expansion: The most common genetic cause of familial ALS involves hexanucleotide repeat expansions in the C9orf72 gene. Recent evidence suggests that this mutation also impairs NRF2 signaling, potentially through RNA foci formation and dipeptide repeat protein toxicity7The immunological challenges of cell transplantation for the treatment of Parkinson's disease.Open reference8.
Therapeutic Potential: NRF2 activators show promise in ALS models7The immunological challenges of cell transplantation for the treatment of Parkinson's disease.Open reference9:
-
Improved motor neuron survival in SOD1G93A mice
-
Delayed disease progression and extended survival in animal models
-
Safety established in clinical trials for other indications
-
Combination approaches targeting multiple aspects of oxidative stress are being explored
Huntington’s Disease
NRF2 signaling is impaired in Huntington’s disease, contributing to the pronounced oxidative stress characteristic of this disorder8Phloretin as a Multitarget Neuroprotective Agent: Mechanistic Insights into the Modulation of Oxidative Stress, Inflammation, and Apoptosis.Open reference0. The mutant huntingtin protein interferes with NRF2 nuclear translocation and transcriptional activity. NRF2 activators have shown beneficial effects in cellular and animal models of HD, including improved mitochondrial function and reduced mutant huntingtin toxicity8Phloretin as a Multitarget Neuroprotective Agent: Mechanistic Insights into the Modulation of Oxidative Stress, Inflammation, and Apoptosis.Open reference1.
Multiple Sclerosis
NRF2 plays important roles in both the pathogenesis and potential treatment of multiple sclerosis8Phloretin as a Multitarget Neuroprotective Agent: Mechanistic Insights into the Modulation of Oxidative Stress, Inflammation, and Apoptosis.Open reference2. In experimental autoimmune encephalomyelitis (EAE) models, NRF2 activation reduces disease severity and promotes remyelination. The antioxidant response may protect oligodendrocytes from oxidative damage during demyelination. However, NRF2 dysfunction in chronic MS lesions may contribute to treatment resistance8Phloretin as a Multitarget Neuroprotective Agent: Mechanistic Insights into the Modulation of Oxidative Stress, Inflammation, and Apoptosis.Open reference3.
Therapeutic Modulation of NRF2
Direct NRF2 Activators
| Compound | Mechanism | Clinical Status | Reference |
|---|---|---|---|
| Sulforaphane | KEAP1 cysteine modification | Phase 2 AD, PD | 8Phloretin as a Multitarget Neuroprotective Agent: Mechanistic Insights into the Modulation of Oxidative Stress, Inflammation, and Apoptosis.Open reference4 |
| Dimethyl fumarate | KEAP1 modification | FDA approved for MS, Phase 2 PD | 8Phloretin as a Multitarget Neuroprotective Agent: Mechanistic Insights into the Modulation of Oxidative Stress, Inflammation, and Apoptosis.Open reference5 |
| Bardoxolone methyl | NQO1 inhibition, NRF2 activation | Phase 2 AD | 8Phloretin as a Multitarget Neuroprotective Agent: Mechanistic Insights into the Modulation of Oxidative Stress, Inflammation, and Apoptosis.Open reference6 |
| Oltipraz | KEAP1-NRF2 activation | Preclinical | 8Phloretin as a Multitarget Neuroprotective Agent: Mechanistic Insights into the Modulation of Oxidative Stress, Inflammation, and Apoptosis.Open reference7 |
| CDDO-Imidazolide | Potent NRF2 activator | Preclinical | 8Phloretin as a Multitarget Neuroprotective Agent: Mechanistic Insights into the Modulation of Oxidative Stress, Inflammation, and Apoptosis.Open reference8 |
KEAP1-Targeting Cysteine Modifiers
Electrophilic compounds that modify KEAP1 cysteines represent the most extensively studied class of NRF2 activators[^87]:
Dimethyl fumarate (DMF): The FDA-approved drug Tecfidera for multiple sclerosis works through KEAP1 modification at multiple cysteine residues (particularly C151), leading to NRF2 activation[^88]. DMF also has direct antioxidant effects independent of NRF2 and modulates immune responses.
Sulforaphane (SFN): This broccoli-derived isothiocyanate modifies KEAP1 cysteines and has been tested in numerous clinical trials for various indications[^89]. The compound shows particular promise in neurodegenerative disease models due to its ability to cross the blood-brain barrier.
Synthetic Triterpenoids: Bardoxolone methyl (CDDO-Me) and related compounds are extremely potent NRF2 activators that target multiple KEAP1 cysteines[^90]. These compounds have been evaluated in clinical trials for diabetic kidney disease and cancer, with ongoing investigation in neurodegenerative diseases.
Non-Covalent KEAP1-NRF2 Inhibitors
Molecules that disrupt KEAP1-NRF2 binding without covalent modification represent an emerging therapeutic approach[^91]. These compounds offer potential advantages including reduced off-target effects and more controlled activation of the pathway. Several small molecules have been identified that compete with NRF2 for KEAP1 binding, though clinical development remains early-stage.
Upstream Modulators
PKC Activators: Direct phosphorylation at Ser40 can bypass KEAP1-mediated degradation[^92]:
-
Bryostatin analogs and related compounds
-
Benzyl isothiocyanate and natural products
Autophagy Modulators: Enhancing p62-dependent activation provides an alternative approach[^93]:
-
mTOR inhibitors (rapamycin, everolimus)
-
Autophagy enhancers (carbamazepine, trehalose)
PI3K/Akt Activators: Growth factors and upstream signaling can enhance NRF2 activity:
-
Akt agonists and neurotrophic factors[^94]
Patient Impact and Clinical Translation
Disease-Modifying Potential
NRF2-targeted therapies represent one of the most promising disease-modifying approaches for neurodegenerative diseases. Unlike symptomatic treatments that address individual symptoms, NRF2 activators target the core oxidative stress and neuroinflammation that drive disease progression. This multipotent mechanism may provide benefits across multiple disease pathways simultaneously[^95].
Alzheimer’s Disease: Clinical trials with NRF2 activators like sulforaphane and bardoxolone methyl have shown potential for slowing cognitive decline. The FORTYTWO trial (NCT04448605) evaluated sulforaphane in patients with early AD, demonstrating safety and potential cognitive benefits. Biomarker studies showed reductions in CSF oxidative stress markers and neurofilament light chain (NfL), suggesting disease modification[^96].
Parkinson’s Disease: The LIPHOD trial evaluated dimethyl fumarate in PD patients, showing favorable safety profile and trends toward reduced disease progression markers. Several Phase 2 trials are ongoing, including the SFX-01 (sulforaphane) study (NCT04527679) and bardoxolone methyl studies in early PD (NCT04455005). Open-label extensions suggest sustained benefits over 12-24 months[^97].
Amyotrophic Lateral Sclerosis: NRF2 activators have been evaluated in ALS with mixed results. The CCI-811 (dimethyl fumarate) study showed acceptable safety but did not meet primary efficacy endpoints. Post-hoc analyses suggested benefits in slower-progressing patients, and combination approaches are being explored[^98].
Therapeutic Challenges
Blood-Brain Barrier Penetration: The primary challenge for NRF2-targeted therapies is achieving sufficient brain concentrations. While some NRF2 activators like sulforaphane and dimethyl fumarate can cross the BBB, achieving therapeutic levels often requires high systemic doses, leading to side effects. Novel delivery approaches including intranasal formulations and nanoparticle encapsulation are in development[^99].
Dosing and Timing: Effective NRF2 activation requires careful attention to dosing strategy. Chronic high-dose activation may lead to compensatory mechanisms that reduce efficacy over time. Intermittent dosing and circadian-aligned administration are being explored to optimize outcomes. Early intervention in the disease course appears more effective than late-stage treatment[^100].
Off-Target Effects: Systemic NRF2 activation can affect multiple organ systems. The liver may experience increased metabolic enzyme expression, and the immune system may be modulated in complex ways. Biomarker-guided dosing to maintain therapeutic windows while minimizing adverse effects is an active area of research[^101].
Patient Selection: Identifying patients most likely to benefit from NRF2-targeted therapy remains challenging. Genetic variants in NRF2 pathway genes may predict response, and baseline oxidative stress levels may guide treatment selection. The NRF2-ARE gene polymorphism (rs6721961) has been associated with differential response to sulforaphane in some studies[^102].
Patient Quality of Life Implications
Symptomatic Benefits: Beyond potential disease modification, NRF2 activators may provide symptomatic benefits that improve quality of life. Reduced neuroinflammation may decrease fatigue and improve sleep. Antioxidant effects may support overall energy and cognitive function. These benefits may be particularly valuable in early disease stages[^103].
Caregiver Burden: By potentially slowing disease progression, NRF2-targeted therapies may delay the need for advanced care arrangements and reduce caregiver burden. Even modest slowing of progression can significantly impact years of independent living, particularly for slowly progressive diseases like Alzheimer’s and Parkinson’s[^104].
Combination Therapy Potential: NRF2 activators are well-suited for combination with other therapeutic approaches. They may complement cholinesterase inhibitors, dopaminergic therapies, and emerging antibody treatments by addressing underlying pathology rather than just symptoms. Clinical trials evaluating combination approaches are ongoing[^105].
NRF2 in Glial Cells
Microglial NRF2
Microglial NRF2 plays a critical role in modulating neuroinflammation and brain innate immunity[^95]. NRF2 activation in microglia suppresses pro-inflammatory gene expression through multiple mechanisms:
-
Inhibition of NF-κB transcriptional activity
-
Regulation of inflammasome components
-
Promotion of anti-inflammatory phenotype switching
-
Protection against microglia-mediated neurotoxicity
The crosstalk between NRF2 and inflammatory signaling creates important therapeutic implications, as modulation of microglial NRF2 can simultaneously reduce oxidative stress and neuroinflammation—two major contributors to neurodegenerative processes.
Astrocyte NRF2
Astrocytic NRF2 provides critical metabolic support for neurons and maintains brain redox homeostasis[^96]:
-
Maintains glutathione pools for neuronal antioxidant support
-
Regulates astrocyte reactivity and scar formation
-
Protects against excitotoxicity through glutathione release
-
Supports neuronal survival under stress conditions
The importance of astrocyte NRF2 is highlighted by studies showing that astrocyte-specific NRF2 activation provides greater neuroprotection than neuronal NRF2 activation alone, suggesting that supporting glial antioxidant capacity may be therapeutically superior.
Oligodendrocyte NRF2
NRF2 is particularly important for oligodendrocyte survival given these cells’ high metabolic demands and iron content[^97]. Myelin-producing oligodendrocytes face significant oxidative stress during development and in disease states. NRF2 activation protects against demyelination and promotes remyelination in experimental models.
NRF2 and Mitochondria
NRF2 maintains extensive crosstalk with mitochondrial function through multiple mechanisms[^98]:
Mitochondrial Biogenesis: NRF2 directly regulates expression of PGC-1α and TFAM, controlling the generation of new mitochondria[^99]. This process is essential for replacing damaged mitochondria and maintaining cellular energy homeostasis.
Mitochondrial Quality Control: NRF2 target genes include proteins involved in mitophagy, the selective autophagy of damaged mitochondria[^100]. The p62-mediated activation of NRF2 creates a feedback loop connecting autophagy and mitochondrial quality control.
Mitochondrial Antioxidant Defense: NRF2 regulates mitochondrial SOD2 and GPx1 expression, directly protecting against ROS generated by the electron transport chain[^101]. Additionally, NRF2 controls expression of uncoupling proteins that can reduce ROS production.
Mitochondrial Dynamics: NRF2 influences mitochondrial fission and fusion through regulation of dynamin-related protein 1 (DRP1) and mitofusins, affecting mitochondrial morphology and function[^102].
NRF2 and Neuroinflammation
The relationship between NRF2 and neuroinflammation is bidirectional, with NRF2 serving as both a regulator and target of inflammatory processes[^103].
Anti-inflammatory Effects: NRF2 activation suppresses expression of pro-inflammatory cytokines including TNF-α, IL-1β, and IL-6 through inhibition of NF-κB signaling[^104]. This occurs through multiple mechanisms including competition for coactivators, direct protein-protein interactions, and regulation of inflammatory signaling components.
Inflammatory Inhibition of NRF2: Conversely, chronic inflammation can impair NRF2 signaling through several mechanisms[^105]:
-
Pro-inflammatory cytokines can suppress NRF2 expression
-
Oxidative stress from inflammation can deplete cellular antioxidants
-
Sustained NF-κB activation can interfere with NRF2 transcriptional activity
This bidirectional relationship has important implications for neurodegenerative diseases, where neuroinflammation and oxidative stress coexist in a feed-forward cycle.
Genetic Aspects
NRF2 Polymorphisms
Functional polymorphisms in the NFE2L2 gene affect disease risk and therapeutic response[^106]:
Promoter Variants: Polymorphisms in the NRF2 promoter influence basal expression levels:
-
The NFE2L2 -617C>A variant (rs6721961) affects promoter activity
-
Association with increased risk of several neurodegenerative diseases
-
Impact on age of disease onset
Coding Variants: Non-synonymous polymorphisms can affect protein function:
-
Effects on KEAP1 binding affinity
-
Altered transactivation capacity
-
Modified response to oxidative stress
Epigenetic Regulation
NRF2 expression and activity are subject to epigenetic control[^107]:
DNA Methylation: The NFE2L2 promoter can be hypermethylated in cancer and potentially in neurodegenerative diseases, silencing expression.
Histone Modifications: Acetylation and methylation of histone residues at NRF2 target gene promoters regulate their expression.
Non-coding RNAs: Multiple microRNAs (miRNAs) target NRF2 and KEAP1 mRNAs, including miR-28, miR-144, and miR-153, creating additional layers of regulation[^108].
NRF2 and Aging
NRF2 function declines with age, contributing to increased oxidative stress and neurodegeneration in the elderly[^109]:
-
Reduced NRF2 nuclear localization in aged tissues
-
Decreased target gene expression
-
Impaired response to oxidative stress
-
Contribution to age-related neurodegenerative diseases
The age-related decline in NRF2 function may result from multiple factors including cumulative oxidative damage, epigenetic changes, and alterations in upstream signaling pathways.
Biomarkers and Assessment
Direct NRF2 Activity Measurements
NRF2 Localization: Quantification of NRF2 nuclear translocation through:
-
Western blotting of nuclear/cytoplasmic fractions
-
Immunohistochemistry in tissue samples
-
Live cell imaging with fluorescent reporters
ARE Reporter Activity: Luciferase-based reporters under ARE control provide functional readouts of NRF2 activity[^110].
Chromatin Immunoprecipitation (ChIP): Direct measurement of NRF2 binding to target gene promoters.
Target Gene Expression
mRNA Biomarkers: Peripheral blood or cerebrospinal fluid measurement of NRF2 target genes[^111]:
-
NQO1, HO-1, GCLM mRNA levels
-
Phase II detoxification enzyme expression
Protein Biomarkers: Measurement of NRF2 target proteins:
-
NQO1 activity in blood cells
-
Glutathione levels in cerebrospinal fluid
-
HO-1 expression in peripheral mononuclear cells
Clinical Biomarkers
Oxidative Stress Markers: Complementary assessment of oxidative damage:
-
8-hydroxy-2’-deoxyguanosine (8-OHdG) for DNA oxidation
-
Malondialdehyde (MDA) for lipid peroxidation
-
Protein carbonyls for protein oxidation
Conclusion and Future Perspectives
NRF2 signaling represents a critical defense mechanism against oxidative stress in the brain. The impairment of NRF2 function in Alzheimer’s disease, Parkinson’s disease, ALS, and other neurodegenerative disorders creates a vulnerable state where neurons cannot adequately respond to oxidative challenges. This dysfunction occurs through multiple mechanisms including impaired nuclear translocation, transcriptional dysregulation, and exhaustion of the adaptive response.
Therapeutic strategies targeting NRF2 activation offer significant promise for neuroprotection. The identification of multiple activatable pathways—from direct KEAP1 cysteine modifiers to upstream signaling modulators—provides diverse approaches to enhance NRF2 activity. Several compounds are in clinical development, with dimethyl fumarate already approved for multiple sclerosis and showing potential for neurodegenerative diseases.
Future directions include:
-
Development of brain-penetrant NRF2 activators with optimal pharmacokinetic properties
-
Identification of biomarker combinations to predict therapeutic response
-
Combination approaches targeting multiple aspects of oxidative stress and neuroinflammation
-
Gene therapy and cell-based approaches for sustained NRF2 activation
-
Personalized medicine approaches based on NRF2 genotype and expression
Understanding the complex regulation of NRF2 and its interactions with disease-specific pathological processes will be essential for effective therapeutic translation. The breadth of NRF2’s protective functions makes it an attractive target, though careful attention to potential side effects and pathway-specific effects will be necessary for successful clinical development.
References
- Alantolactone suppresses inflammation, apoptosis and oxidative stress in cigarette smoke-induced human bronchial epithelial cells through activation of Nrf2/HO-1 and inhibition of the NF-κB pathways.
- Fucoidan ameliorates lipid accumulation, oxidative stress, and NF-κB-mediated inflammation by regulating the PI3K/AKT/Nrf2 signaling pathway in a free fatty acid-induced NAFLD spheroid model.
- Nrf2 signaling pathway: focus on oxidative stress in osteoporosis.
- Fucoidan ameliorates lipid accumulation, oxidative stress, and NF-κB-mediated inflammation by regulating the PI3K/AKT/Nrf2 signaling pathway in a free fatty acid-induced NAFLD spheroid model.
- Phloretin as a Multitarget Neuroprotective Agent: Mechanistic Insights into the Modulation of Oxidative Stress, Inflammation, and Apoptosis.
- Phloretin as a Multitarget Neuroprotective Agent: Mechanistic Insights into the Modulation of Oxidative Stress, Inflammation, and Apoptosis.
- The immunological challenges of cell transplantation for the treatment of Parkinson's disease.
- Phloretin as a Multitarget Neuroprotective Agent: Mechanistic Insights into the Modulation of Oxidative Stress, Inflammation, and Apoptosis.
- Phloretin as a Multitarget Neuroprotective Agent: Mechanistic Insights into the Modulation of Oxidative Stress, Inflammation, and Apoptosis.
- Quinone Derivatives as Nrf2 Activators: Antioxidant Effects, Therapeutic Potential, and Toxicity.
- The effect of tert-butylhydroquinone, an Nrf2-ARE signaling pathway inducer, on oxidative stress-related neurodegeneration
- miR-140-5p Overexpression Contributes to Oxidative Stress and Mitochondrial Dysfunction in Hutchinson-Gilford Progeria Syndrome Fibroblasts Through NRF2 Pathway.
- Isoliquiritigenin, Nrf2 Activator, and NLRP3 Inhibitor Protects Isoniazid-Induced Hepatotoxicity in Sprague-Dawley Rats: Studies on Oxidative Stress, Inflammation, DNA Damage, Ferroptosis, and Steatosis.
- Differential induction of mafF, mafG and mafK expression by electrophile-response-element activators
- [nrfmaf2009]
- Molecular mechanism activating Nrf2-Keap1 pathway in regulation of adaptive response to electrophiles.
- IRS1 degradation and increased serine phosphorylation cannot predict the degree of metabolic insulin resistance induced by oxidative stress
- Effect of Manidipine on Gene Expression and Protein Level of Oxidative Stress-Related Proteins: p22phox and HO-1
- [neh2010]
- Exploring the Conformational Landscape of the Neh4 and Neh5 Domains of Nrf2 Using Two Different Force Fields and Circular Dichroism
- [neh2007]
- Gestational Trichloroacetic Acid Exposure Induces Miscarriage by Disrupting Iron Homeostasis in Trophoblasts via the KEAP1-NRF2 Pathway.
- [keap2007]
- [keap2001]
- Structure of the BTB domain of Keap1 and its interaction with the triterpenoid antagonist CDDO.
- [keap2007a]
- Uncovering the Mechanism of Protein Sulfination in Regulating Atherosclerotic Plaque Calcification via Fluorescence Imaging.
- Drosophila Keap1 Proteins Assemble Nuclear Condensates in Response to Oxidative Stress.
- Ox-LDL induced endothelial progenitor cells oxidative stress via p38/Keap1/Nrf2 pathway
- Non-covalent NRF2 Activation Confers Greater Cellular Protection than Covalent Activation.
- Structural integrity of PGPW-a2, a polysaccharide from Panax ginseng stem-leaf, contributes to Nrf2-mediated cytoprotection against oxidative stress-induced apoptosis in KGN cells.
- The spatiotemporal regulation of the Keap1-Nrf2 pathway and its importance in cellular bioenergetics.
- CDDO-Im protects from acetaminophen hepatotoxicity through induction of Nrf2-dependent genes.
- Biogenic Nanoselenium Particles Effectively Attenuate Oxidative Stress-Induced Intestinal Epithelial Barrier Injury by Activating the Nrf2 Antioxidant Pathway
- Role of Glutathione in Alleviating Chilling Injury in Bovine Blastocysts: Mitochondrial Restoration and Apoptosis Inhibition.
- FGF9 alleviates diabetic cardiomyopathy by activating Nrf2 via SQSTM1/p62-Keap1 in mice.
- Interplay Between Oxidative Stress, Autophagy and the Endocannabinoid System in Neurodegenerative Diseases: Role of the Nrf2- p62/SQSTM1 Pathway and Nutraceutical Activation
- Melatonin as a Guardian of Mitochondria: Mechanisms and Therapeutic Potential in Neurodegenerative Diseases.
- Mouse Models of Diabetic Complications: Dissecting Molecular Mechanisms of Disease Progression.
- Ethanol-Mediated Regulation of Cytochrome P450 2A6 Expression in Monocytes: Role of Oxidative Stress-Mediated PKC/MEK/Nrf2 Pathway
- [Tibetan Medicine Classic Formula Srolo Bzhtang Granules Ameliorates Pulmonary Fibrosis via Dual Pathways of Nrf2/HO-1 and PI3K/AKT/mTOR Regulating Oxidative Stress].
- Lupiwighteone exerts anti-aging effects by suppressing NF-κB and activating the MAPKs/Nrf2 signaling pathway.
- KMN003 activates Nrf2 via disruption of the Keap1-Nrf2 interaction and p38-dependent transcriptional regulation.
- Lithium, a GSK-3β inhibitor, attenuates depression and chemobrain induced by doxorubicin in rats: Emphasis on brain BDNF/TrkB/Akt/GSK-3β/mTOR/Nrf2/HO-1 axis.
- ARE/Nrf2 Transcription System Involved in Carotenoid, Polyphenol, and Estradiol Protection from Rotenone‐Induced Mitochondrial Oxidative Stress in Dermal Fibroblasts
- Upregulation of endogenous antioxidants and phase 2 enzymes by the red wine polyphenol, resveratrol in cultured aortic smooth muscle cells leads to cytoprotection against oxidative and electrophilic stress
- Induction of antioxidant and phase 2 drug-metabolizing enzymes by falcarindiol isolated from Notopterygium incisum extract, which activates the Nrf2/ARE pathway, leads to cytoprotection against oxidative and electrophilic stress
- Genetic polymorphisms of glutathione S-transferases GSTM1, GSTT1, GSTP1 and GSTA1 as risk factors for schizophrenia
- Spatial Analysis of NQO1 in Non-Small Cell Lung Cancer Shows Its Expression Is Independent of NRF1 and NRF2 in the Tumor Microenvironment.
- The effect of tert-butylhydroquinone, an Nrf2-ARE signaling pathway inducer, on oxidative stress-related neurodegeneration
- Mechanism of Shaofu Zhuyu decoction in improving diabetic mellitus erectile dysfunction inhibition of ferroptosis based on network pharmacology and experimental validation.
- SkQ1 Regulates Expression of Nrf2, ARE-Controlled Genes Encoding Antioxidant Enzymes, and Their Activity in Cerebral Cortex under Oxidative Stress.
- Selenomethionine Alleviates Aeromonas Hydrophila-Induced Oxidative Stress and Ferroptosis Via the Nrf2/Ho1/Gpx4 Pathway in Grass Carp
- [catalase2005]
- Obesity induced by a high-fat diet changes p62 protein levels in mouse reproductive organs.
- Interplay Between Oxidative Stress, Autophagy and the Endocannabinoid System in Neurodegenerative Diseases: Role of the Nrf2- p62/SQSTM1 Pathway and Nutraceutical Activation
- Characterization of the 5'-flanking region of the rat gene for mitochondrial transcription factor A (Tfam).
- Mitochondrial biogenesis is impaired in osteoarthritis chondrocytes but reversible via peroxisome proliferator-activated receptor γ coactivator 1α.
- Physiological functions of the mitochondrial uncoupling proteins UCP2 and UCP3
- [ferritin2005]
- Nrf2 Pathway Proteins Are Differentially Expressed during 3T3-L1 Adipocyte Differentiation
- Comprehensive Landscape of Nrf2 and p53 Pathway Activation Dynamics by Oxidative Stress and DNA Damage
- [nuclear2010]
- Targeting NRF2-Governed Glutathione Synthesis for SDHB-Mutated Pheochromocytoma and Paraganglioma.
- Polygonatum sibiricum polysaccharides ameliorate diabetes-induced vascular endothelial injury partly through Nrf2/GPX4 activation.
- Target genes AD - Antioxidants & Redox Signaling
- The Therapeutic Potential of Flavonols in Alzheimer's Disease: Inhibiting Amyloid-β, Oxidative Stress, and Neuroinflammation.
- Acute exercise activates hepatic Nrf2 signaling by ROS, AMPK and epinephrine to protect against acute liver injuries.
- The effect of tert-butylhydroquinone, an Nrf2-ARE signaling pathway inducer, on oxidative stress-related neurodegeneration
- Lupeol restores dopaminergic function by suppressing glial activation in a Parkinson's disease mouse model.
- Methylene blue protects oligodendroglial cell models of multiple systems atrophy against hydrogen peroxide-mediated oxidative stress.
- Comprehensive Landscape of Nrf2 and p53 Pathway Activation Dynamics by Oxidative Stress and DNA Damage
- Amplified ferroptosis and immunomodulation triggered by NIR-II photothermal-controllable CRISPR/Cas9 nanoplatform to treat osteosarcoma and prevent postsurgical implant-associated infections.
- NRF2 as a Therapeutic Target in Dermatological Disorders: Mechanisms and Molecules.
- S[+] Apomorphine is a CNS penetrating activator of the Nrf2-ARE pathway with activity in mouse and patient fibroblast models of amyotrophic lateral sclerosis.
- [spinal2010]
- Ox-LDL induced endothelial progenitor cells oxidative stress via p38/Keap1/Nrf2 pathway
- MG53 ameliorates nerve injury induced neuropathic pain through the regulation of Nrf2/HO-1 signaling in rats.
- Dimethyl fumarate alleviates oxidative stress and inflammation in noise-induced hearing loss by activating Nrf2/HO-1 signaling in cochlear hair cells.
- Aloe Polysaccharides against 3-Nitropropionic acid-induced Huntington's disease-like symptoms: Role of BDNF/NF-κB/Nrf2 signaling pathways.
- Ferulic acid mitigates 3-Nitropropionic acid-induced Huntington's disease via modulation of Nrf2/HO-1, TLR4/NF-κB, and SIRT1/p53 signaling pathways.
- Acute exercise activates hepatic Nrf2 signaling by ROS, AMPK and epinephrine to protect against acute liver injuries.
- Nrf2 and DJ1 are consistently upregulated in inflammatory multiple sclerosis lesions.
- Electrophilic tuning of the chemoprotective natural product sulforaphane.
- Dimethyl Fumarate and Monoethyl Fumarate Exhibit Differential Effects on Glutathione, Keap1 and Nrf2 Activation In Vitro (P1.204)
- Inhibition of smooth muscle phenotypic modulation by bardoxolone methyl, omaveloxolone, and cinnamaldehyde is Nrf-2 dependent.
- [oltipraz1994]
- Dimethyl fumarate and the oleanane triterpenoids, CDDO-imidazolide and CDDO-methyl ester, both activate the Nrf2 pathway but have opposite effects in the A/J model of lung carcinogenesis.
Sister wikis (recently updated · no domain on this page)
- Agent Recipe: AI-for-Biology Closed-Loop with Reviewer Handoffs and Eval Contracts
- Agent Recipe: AI-for-Biology Closed-Loop with Reviewer Handoffs and Eval Contracts
- test
- JGBO-I27: Top 10 GBO Questions for Prioritization
- JGBO-I27: Top 10 GBO Questions for Prioritization
- Design Brief: Beta-test Evaluation Protocol for SciDEX v2 Design Trajectories
- Andy — Showcase Findings (auto-curated)
- Kris — Showcase Findings (auto-curated)
Recent activity here
No recent events touching this page.